Search - tctmd.com

Displaying 141 - 160 of 274

Sort: Relevancy | Date

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

News Daily News

Mobile Health Technologies May Boost Diagnosis, Care for Patients With Structural Heart Disease

Yael L. Maxwell

September 15, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Daily News

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Caitlin E. Cox

April 21, 2017

News Daily News

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

L.A. McKeown

April 12, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Daily News

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Michael O'Riordan

February 09, 2017

News Daily News

Transfemoral PCI More Successful in Treating CTOs, Especially Complex Lesions

Yael L. Maxwell

February 07, 2017

News Daily News

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

Michael O'Riordan

January 26, 2017

News Daily News

FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy

L.A. McKeown

October 27, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

Shelley Wood

September 29, 2016

News Daily News

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Shelley Wood

September 29, 2016

News Daily News

Rapid Treatment Remains Key for Thrombectomy in Acute Stroke but Still Works Several Hours After Onset

Todd Neale

September 27, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

L.A. McKeown

August 24, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

Advertisement

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Mobile Health Technologies May Boost Diagnosis, Care for Patients With Structural Heart Disease

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Transfemoral PCI More Successful in Treating CTOs, Especially Complex Lesions

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Rapid Treatment Remains Key for Thrombectomy in Acute Stroke but Still Works Several Hours After Onset

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content